Navigation Links
The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K
Date:9/27/2010

AURORA, Colo., Sept. 27 /PRNewswire/ -- The Colorado Institute for Drug, Device and Diagnostic Development (CID4) has completed the selection process from its first solicitation announced in February.  The announcement is made by Richard C. Duke, Ph.D., CID4 President/CEO, who says, "Boulder-based Sophono, Inc., is receiving $600,000 for its Alpha 1 Magnetic Bone Anchored Hearing System; and Aurora-based PeptiVir, Inc., is receiving $300,000 for its universal flu vaccine under development."

In addition to initial financial support from the state, CID4 also received federal support from Fitzsimons Redevelopment Authority via a Senate appropriation supported by Colorado Senator Michael Bennet.  Senator Bennet says, "We can strengthen our economic recovery and ensure Colorado remains a leader in innovation and entrepreneurship by supporting efforts that turn groundbreaking research into startups and companies that will grow and create good-paying jobs."

Further, Colorado Governor Bill Ritter, says: "Supporting Colorado's life sciences companies is critical to growing jobs and our economy in Colorado, and I congratulate both the CID4 for success in its first solicitation and those companies chosen to receive funding."

"Sophono's Alpha 1 has received its CE mark and is being sold in Europe.  Our investment will allow Sophono to accelerate its FDA clearance process," Kevin M. Smith, CID4 Executive Vice President/COO, explains. In addition, according to Sophono's President/CEO Jim Kasic, the company plans to relocate manufacturing and assembling operations from Germany to Boulder, resulting in the hiring of 6-10 employees. Visit http://www.sophono.com.  

PeptiVir, Inc., is an early stage biopharmaceutical company focused on the development and commercialization of a conformationally-constrained, synthetic peptide-based vaccine platform for prevention of viral diseases. "There is an urgent need to develop new and different influenza vaccines," Kathryn Holmes, Professor of Microbiology, University of Colorado School of Medicine and a PeptiVir founder, says.  

About CID4

CID4 is transforming life science innovation into commercial success by identifying and funding potential opportunities, and utilizing the talents of an advanced leadership team to ensure ultimate market value. Visit http://www.cid4.com.


'/>"/>
SOURCE The Colorado Institute for Drug, Device and Diagnostic Development
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Colorado Cancer Research Program Will Host Golf Event to Drive the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer
2. American Lung Association in Colorados Faces of Influenza Initiative Rolls Up its Sleeves to Kick Off Flu Season in Denver
3. Denver-Ft. Collins Ophthalmologist First in Colorado to Implant nanoFLEX Lens
4. Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings
5. Colorado-Based Spectranetics Corporation to Pay $5 Million to Resolve Allegations Relating to its Medical Devices
6. Forensic Laboratories Selected for Colorado Companies to Watch Award
7. CO-REC Ready to Assist Colorado Health Care Providers in Implementing Electronic Health Record Systems and Achieving Meaningful Use
8. Tahoma, Colorado Springs and Salt Lake City Have the Highest Percentage of HIV Patients in the U.S. Who Are Left Untreated
9. Tacoma, Colorado Springs and Salt Lake City Have the Highest Percentage of HIV Patients in the U.S. Who Are Left Untreated
10. AlloSource Named Colorados Top Healthcare Company
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... 28, 2016 Treato , ... healthcare, announced today that it has been named a ... Vendor in Life Sciences, 2016, Stephen Davies ... report focuses on life-science- oriented analytics, algorithms and smart ... and doctors, confirm medication ingestion, and analyze unstructured information. ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... ... of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused ... half the issue representing international (non-US) based authors, the third volume of PXJ ...
(Date:5/2/2016)... ... 02, 2016 , ... Beanfields, PBC, makers of Beanfields Bean ... students at University of Colorado in Boulder to create new advertising campaigns. , ... the School of Journalism, who selected Beanfields as the brand on which to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life ... better understand life insurance throughout various life stages. , The site launched on ... needs calculator and content specific to the times when life insurance matters most. ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... for the 2016 Main Residency Match® (“the Match”), the system through which U.S. ... teaching institutions. A record-high 30,750 positions were placed in the 2016 Match, and ...
(Date:5/2/2016)... New York, NY (PRWEB) , ... May 02, 2016 , ... ... Highlighting the year’s best in pet gear and toys, leading product review site ... TTPM Pets Paw of Excellence Awards at their Spring Showcase at the Metropolitan ...
Breaking Medicine News(10 mins):